---
title: "Pasqal IPO and Funding: PSQL Listing, Investors and Cash at Close"
description: "Pasqal completed its public-market transaction in August 2026. Understand the PSQL listing, earlier investors and why $360 million of closing cash is not a new venture round."
date: 2026-10-26T00:00:00.000Z
source: https://venturecapitaltracker.com/pasqal-ipo-funding-investors
---

# Pasqal IPO and Funding: PSQL Listing, Investors and Cash at Close

> Pasqal completed its public-market transaction in August 2026. Understand the PSQL listing, earlier investors and why $360 million of closing cash is not a new venture round.

**Pasqal is no longer simply a pre-IPO quantum startup.** It completed its business combination with Bleichroeder Acquisition Corp. II on August 27, 2026. Its public-company materials identify Nasdaq ticker **PSQL**; the closing announcement scheduled trading to begin on August 28.

The financing story needs one important distinction: the approximately **$360 million of cash available at closing** is not labeled as a new venture round, company valuation or net offering proceeds. Those measures answer different questions.

## Pasqal's listing and funding at a glance

| Question | Answer |
|---|---|
| Is Pasqal public? | Yes; the business combination completed in August 2026 |
| What is its ticker? | PSQL on Nasdaq |
| Was this a conventional IPO? | No. It was a business combination with a listed special-purpose acquisition company, or SPAC |
| What does the $360M figure represent? | Approximately the cash available at closing, according to the company |
| What earlier venture round is verified here? | A €100M Series B announced in January 2023, led by Temasek |

Sources: the [completed business-combination announcement](https://www.pasqal.com/newsroom/pasqal-and-bleichroeder-acquisition-corp-ii-complete-business-combination/) and the [historical Series B release](https://www.pasqal.com/newsroom/pasqal-raises-e100-million-series-b-funding-to-advance-neutral-atoms-quantum-computing/). This is a selected transaction history, not a complete ownership register.

## Why closing cash is not the same as money raised

Imagine a business arriving at a transaction with cash already on its balance sheet. New financing, transaction expenses and other movements can then change the cash available after closing. The final balance is useful, but it does not by itself tell a reader how much fresh equity was issued.

That is why VCT leaves the proceeds amount unresolved when the source provides only a closing-cash figure. Replacing it with a more convenient number would make comparisons look precise while answering the wrong question.

The same principle applies to valuation. A cash balance is an asset; a valuation measures what investors assign to the business or its equity. Neither can be inferred from the other without additional information.

## Who backed Pasqal before the listing?

Temasek led the disclosed €100 million Series B. Named participants included the European Innovation Council Fund, Wa'ed Ventures, Bpifrance Large Venture, Quantonation, the Defense Innovation Fund, Daphni and Eni Next.

The release's dateline is January 24, 2023, while the webpage displays January 23. We use the release dateline for the canonical record and preserve that distinction in its notes.

These names establish participation in that particular financing. They do not reveal each investor's check, ownership percentage after the listing or whether it participated in every later transaction.

The [Pasqal company profile](/startup/pasqal) contains the structured history. The broader [quantum-computing investor guide](/quantum-computing-investors-funds-and-portfolio-companies) connects investors to other disclosed rounds.

## What does Pasqal build?

Pasqal develops neutral-atom quantum systems, supplied with software and available through customer installations and cloud access. Its closing materials distinguish current analog computing from its intended path toward fault-tolerant machines.

That distinction is useful for readers: a product available today and a future architecture milestone should not be evaluated as though they are the same deliverable.

For a buyer, the first question is what workload the available system can actually run. For an investor, the next question is how development progress could change demand, operating costs or the value of an installed system.

A roadmap can help organize those questions. It cannot substitute for a demonstrated result.

## How to compare Pasqal with neutral-atom peers

| Company | Useful comparison | What financing cannot establish |
|---|---|---|
| [QuEra](/startup/quera-computing) | Product scope and progress from analog systems toward error-corrected computation | That a larger announced financing proves a better machine |
| [Atom Computing](/startup/atom-computing) | System delivery, reliability and the requirements of customer installations | That a cumulative funding headline is a new round |
| [planqc](/startup/planqc) | Development milestones and the mix of private and public support | That an entire financing package is equity |
| [Oratomic](/startup/oratomic) | The evidence supporting its fault-tolerance approach | That a private valuation is a technical benchmark |

Our [neutral-atom funding comparison](/quera-funding-investors-neutral-atom-comparison) explains the financing differences. These companies share a broad hardware category, not an identical product or business model.

## What becomes more important after a listing?

Our analysis is that public-market access changes the questions investors can ask more than it changes the underlying engineering challenge.

**Revenue composition matters.** A system sale, a research contract and recurring access revenue can have different margins and renewal patterns. A useful comparison needs their contribution and obligations, not only a headline growth percentage.

**Cash requirements matter.** Development plans need to be connected to operating cash use, manufacturing investment and contractual commitments. Closing cash alone does not determine runway.

**Dilution matters.** New shares, warrants and other instruments can affect existing shareholders differently. A financing headline cannot replace the relevant filings and terms.

**Repeatable customer outcomes matter.** A deployment is useful evidence of execution, but commercial success still depends on what customers can achieve and whether they return for more.

These are evaluation questions, not a forecast about Pasqal's returns. This guide does not provide a live share price, price target or recommendation to buy the stock.

## The takeaway

The useful update is not another speculative IPO date: Pasqal's transaction has closed. Its funding history now spans private venture capital and public-market financing, which should be compared on their own terms.

Read the [quantum companies and funding guide](/2026-quantum-computing-funding-landscape-investors-startups) for the wider market, or compare this route with [Quantinuum's conventional IPO](/quantinuum-ipo-funding-history).

*Reviewed October 26, 2026. Dates distinguish closing from the announced trading schedule. Historical investor participation is not a current ownership table. Closing cash is not presented as proceeds or valuation.*

**By:** [Venture Capital Tracker](https://venturecapitaltracker.com/editorial-policy)

**Editorial note:** AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.